Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00124293 |
This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.
Condition | Intervention |
---|---|
Traumatic Brain Injury |
Drug: activated recombinant human factor VII |
Study Type: | Observational |
Official Title: | A Multi Centre Observational Study to Evaluate the Incidence and Magnitude of Haemorrhagic Progression of Cerebral Contusions and the Identification of Important Safety Issues Following Traumatic Brain Injury |
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria: - Ages Eligible for Study: 18 Years - 85 Years
Study Director: | Brett Skolnick, PhD | Novo Nordisk |
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | F7CBI-1587 |
Study First Received: | June 30, 2005 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00124293 History of Changes |
Health Authority: | United States: Institutional Review Board |
Craniocerebral Trauma Contusions Wounds and Injuries Disease Progression Disorders of Environmental Origin |
Central Nervous System Diseases Trauma, Nervous System Brain Diseases Brain Injuries |
Craniocerebral Trauma Nervous System Diseases Wounds and Injuries Disorders of Environmental Origin |
Central Nervous System Diseases Trauma, Nervous System Brain Diseases Brain Injuries |